Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer
- 1 May 2015
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 113 (03) , 593-598
Abstract
Cancer is a risk factor for venous thromboembolism (VTE). Elevated plasma D-dimer and fibrinogen levels are also risk factors for VTE. Furthermore, in patients with metastatic breast cancer (MBC), the presence of circulating tumour cells (CTCs) is a risk factor for VTE. The relationship between CTCs and D-dimer is unknown. The aim of this study was to determine whether CTCs correlate with plasma D-dimer level, fibrinogen level, and risk of VTE in MBC. This prospective study included 47 MBC patients treated from July 2009 through December 2010 at the MD Anderson Cancer Center. CTCs in peripheral blood were detected and enumerated using the CellSearch system. D-dimer and fibrinogen were measured in plasma at the time of CTC detection. Thirty-three patients (70 %) had ≥ 1 CTC, and 22 patients (47 %) had ≥ 5 CTCs. Patients with ≥ 1 CTC or ≥ 5 CTCs had significantly higher mean plasma D-dimer levels (g/mL) than patients with no CTCs and < 5 CTCs (2.48 and 3.31 vs 0.80 and 0.84, respectively; p=0.006 for cut-off ≥ 1 CTC and p=0.003 for cut-off ≥ 5 CTCs). In multivariate analysis, presence of CTCs and number of metastases were positively associated with plasma D-dimer level. CTCs were not associated with plasma fibrinogen level. At median follow-up of 13.5 months, three of 33 patients (9 %) with ≥ 1 CTC had VTE, vs no patients with undetectable CTCs. In conclusion, the presence of CTCs was associated with higher levels of plasma D-dimer in MBC patients. This study further confirms an association between CTCs and risk of VTE.Keywords
Funding Information
- State of Texas Rare and Aggressive Breast Cancer Research Program (CA138239–02)
This publication has 30 references indexed in Scilit:
- Circulating tumour cells in non-metastatic breast cancer: a prospective studyThe Lancet Oncology, 2012
- Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell countsAnnals of Oncology, 2010
- Increases in Quantitative D-Dimer Levels Correlate With Progressive Disease Better Than Circulating Tumor Cell Counts in Patients With Refractory Prostate CancerAmerican Journal of Clinical Pathology, 2010
- Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patientsBritish Journal of Cancer, 2009
- Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancerBritish Journal of Cancer, 2008
- Tissue factor‐bearing microparticles derived from tumor cells: impact on coagulation activationJournal of Thrombosis and Haemostasis, 2008
- Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell functionJournal of Thrombosis and Haemostasis, 2008
- Elevated tissue factor procoagulant activity in CD133‐positive cancer cellsJournal of Thrombosis and Haemostasis, 2007
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- The Thrombogenic Effect of Anticancer Drug Therapy in Women with Stage II Breast CancerNew England Journal of Medicine, 1988